Neuphoria Therapeutics Reports $9.9 Million Net Loss and Increased R&D Expenses

Neuphoria Therapeutics Inc. reported a net loss of $9.9 million for the three months ending September 30, 2025, a significant increase from a loss of $0.8 million during the same period in 2024. The company's total operating expenses rose to $5.7 million, up from $3.6 million year-over-year, primarily driven by increased research and development costs associated with its lead drug candidate, BNC210. Research and development expenses nearly doubled to $3.8 million, reflecting heightened activity in clinical trials, particularly for PTSD and social anxiety disorder (SAD). The company has not yet generated any product revenues and continues to operate at a loss, with an accumulated deficit of $188.3 million as of the end of the reporting period.

In terms of financial position, Neuphoria's total assets decreased to $27.3 million from $28.6 million at the end of the previous fiscal year. Cash and cash equivalents stood at $13.6 million, down from $14.2 million, while current liabilities increased to $5.1 million from $4.2 million. The company’s total liabilities surged to $14.8 million, largely due to a rise in the fair value of its accompanying warrants liability, which increased from $3.7 million to $8.1 million. This change reflects the volatility in the market and the company's ongoing financing activities.

Strategically, Neuphoria has undergone significant organizational changes, including its re-domiciliation from Australia to Delaware, which was completed on December 23, 2024. The company has also initiated a strategic review of its operations following the disappointing results from the AFFIRM-1 Phase 3 trial for BNC210 in SAD, which did not meet its primary endpoint. As a result, Neuphoria plans to discontinue the SAD program and focus on further development of BNC210 for PTSD. The company is also exploring strategic alternatives, including potential mergers or partnerships, to enhance shareholder value.

Operationally, Neuphoria's workforce has expanded, with an increase in employee headcount contributing to higher general and administrative expenses, which rose to $1.9 million from $1.7 million year-over-year. The company is actively engaged in clinical trials, with approximately 90% of its research and development expenses allocated to BNC210. Despite the challenges, Neuphoria believes its existing cash and cash equivalents, bolstered by recent equity issuances, will be sufficient to fund operations through at least the second quarter of fiscal year 2027.

Looking ahead, Neuphoria remains focused on advancing its clinical programs while managing its financial resources prudently. The company acknowledges the inherent risks in drug development and the need for additional capital to support its ongoing research and development efforts. Neuphoria's management has expressed confidence in its ability to navigate these challenges, although it recognizes the uncertainties that could impact its future performance and operational plans.